Tenax Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Tenax Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Tenax Therapeutics: 6 sponsored US clinical trials, 2 recruiting.
Tenax Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Right Sided Heart Failure With Normal Ejection Fraction, with 1 trials.
Upper-quartile sponsor footprint
Tenax Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
NCT03624010
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
NCT03541603
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
NCT02025621
Study of Oxycyte in Severe Closed Head Injury
NCT00174980
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 3 |
What is open in the Tenax Therapeutics pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Right Sided Heart Failure With Normal Ejection Fraction (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tenax Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Tenax Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Tenax Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Tenax Therapeutics or any single study.
- 2 of Tenax Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Right Sided Heart Failure With Normal Ejection Fraction is the condition Tenax Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Right Sided Heart Failure With Normal Ejection Fraction trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tenax Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.